Clinical and Patient-Reported Outcomes in C-POST: Phase 3 Trial of Adjuvant Cemiplimab versus Placebo for High-Risk Cutaneous Squamous Cell Carcinoma
Clinical and Patient-Reported Outcomes in C-POST: Phase 3 Trial of Adjuvant Cemiplimab versus Placebo for High-Risk Cutaneous Squamous Cell Carcinoma
D. Rischin,C. Chen,28 Authors,A. M. Lim
2026 · DOI: 10.1016/j.ejcskn.2026.100962
EJC Skin Cancer · 0 Citations